PRNewsWire
26 Aug 2026, 06:36 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen · Founder & analyst
What the story claims
5 claims · each scored for market impact
Biohaven will receive $400 million in immediate non-dilutive cash consideration from SK Biopharmaceuticals. — A significant cash infusion without equity dilution strengthens Biohaven's balance sheet and reduces immediate funding risk.
+0.80SK Biopharmaceuticals has obtained an exclusive worldwide license to Biohaven's Kv7 ion channel platform and lead candidate opakalim. — Transferring the asset to a partner with a proven track record in epilepsy (XCOPRI) increases the probability of successful commercialization.
+0.60Biohaven is eligible for up to $795 million in total milestone payments plus tiered royalties on net sales. — Provides substantial long-term upside and valuation support based on clinical and regulatory success.
+0.50Continue reading
6 related stories
Top 1 mover · tap to explore
SK Biopharmaceuticals will assume all future Kv7 program costs, including $245 million in obligations to Knopp Biosciences. — De-risks Biohaven's financials by shifting R&D and liability costs to the partner.
+0.40Topline results for the opakalim RISE3 trial are expected in the second half of 2026. — Establishes the near-term catalyst timeline for the asset's clinical validation.
+0.30Which stocks this story touches
The company secured a strategic licensing deal bringing in $400 million in immediate non-dilutive capital and potential milestones up to $795 million.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Seeking Alpha
6h ago
